Exabis Library
Welcome to the e-CCO Library!
P437: Higher adalimumab maintenance regimens are more effective than standard maintenance doses in Crohn’s disease patients who have failed infliximab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P437: Hyperbaric oxygen therapy for Inflammatory Bowel Disease – a systematic review
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P437: Reoperations and long-term survival of Kock’s continent ileostomy in Inflammatory bowel disease patients: a population based national cohort study from Sweden.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P437: Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P438 Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P438: Adalimumab dose escalation and de-escalation in ulcerative colitis: incidence and predictors of success. A real life Belgian cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P438: Efficacy and safety of ustekinumab for Ulcerative Colitis through 4 years in Asian patients: Final results from the sub-population of UNIFI long-term extension
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P438: Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are rare but insidious adverse events: data from a large single-centre cohort
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P438: Maladaptive decision-making is associated with psychological morbidity in people with Inflammatory Bowel Disease.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P438: Reinduction with ustekinumab in Crohn’s disease patients with a loss of response to treatment
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P438: The Efficacy and Safety of ustekinumab Therapy in refractory Inflammatory Bowel Disease (IBD) patients with co-morbidities and old age.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P438: The inflammatory bowel disease disability index applied to ileal pouch anal anastomoses in New Zealand
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P439 Patient’ recruitment for a Phase 3 inflammatory bowel disease (IBD) programme is significantly increased when accessing the CT-SCOUT™ platform
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P439: Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P439: Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P439: Effectiveness of a training programme on motivational interviewing skills applied to inflammatory bowel disease management
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P439: Effectiveness of Ustekinumab on Crohn's disease associated spondyloartropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P439: Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P439: Monitoring inflammatory Bowel disease activity in a virtual biologic clinic: The effects of proactive therapeutic drug monitoring on patient reported outcome measures
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P439: Stability of subcutaneous serum IFX (CTP13) levels between two injections and over two successive cycles in patients with Crohn's disease.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM